***Sponsored by LFG Equities Corp
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
NLSP carries zero long-term debt, a rarity among biopharmaceutical companies
READ THE INVESTOR PRESENTATION HERE
________________________
Hello Everyone,
We’re coming off another action-packed week in the markets — full of volatility, heavy swings, and uncertainty. But even in the chaos, some companies are showing resilience and moving steadily forward. One of those names you should be watching closely is NLS Pharmaceutics (NASDAQ: NLSP).
Why NLSP Stands Out
NLSP is a clinical-stage pharmaceutical company developing innovative therapies for patients with rare and complex central nervous system (CNS) disorders — particularly in areas where existing treatments are insufficient or non-existent.
One of the fastest-growing sectors in global healthcare is ADHD, a market projected to reach $70+ billion by 2032. NLSP’s lead candidate, Mazindol ER, directly addresses this space — and more.
Mazindol ER: A Phase 3-Ready Asset with Broad Potential
Mazindol ER is an extended-release formulation of a well-studied compound with a proven safety profile. It’s Phase 3-ready for both:
- Attention Deficit Hyperactivity Disorder (ADHD)
- Narcolepsy and Excessive Daytime Sleepiness (EDS)
With Orphan Drug Designation in both the U.S. and Europe, and a strong Phase 2 data package in hand, Mazindol ER is positioned to move swiftly through the regulatory pipeline. The upcoming AMAZE Phase 3 trial will focus on adult patients with narcolepsy, a $4.5 billion market projected by 2027.
Strategic Expansion: Tackling the Opioid Crisis
In a significant step beyond CNS and sleep disorders, NLS also holds a U.S. patent for the use of Mazindol ER in treating opioid use disorder, including heroin and fentanyl addiction. A preclinical study targeting fentanyl addiction is underway and is expected to yield promising results.
This positions NLSP within the $5 billion opioid addiction treatment market, a high-priority area for the U.S. government and public health institutions. With fentanyl-related overdoses now the leading cause of drug-related deaths in the U.S., the need for non-opioid alternatives has never been greater. Mazindol ER’s unique pharmacological profile — modulating dopaminergic and noradrenergic pathways without being addictive — makes it a compelling candidate in this space.
Corporate HIGHLIGHTS
- Clean balance sheet: No debt, $3.2M raised, 12-month cash runway
- Nasdaq compliance regained
- Merger in progress: Binding term sheet signed with Kadimastem, a clinical-stage biotech with complementary assets and commercial expertise
- Pipeline strength: Over 100 patents in 140+ countries covering CNS, ADHD, cancer fatigue, Parkinson’s, and more
- Named Patient Program launched in Europe for idiopathic hypersomnia
- Multiple partnerships: Including Université de Lausanne, University of Berne, Swiss Narcolepsy Network, and patient advocacy organizations such as Narcolepsy Network and Hypersomnia Foundation
Product Pipeline Highlights
- Quilience® – Targeting EDS and cataplexy in narcolepsy
- Nolazol® – In development for ADHD and related neurodevelopmental disorders
- IsletRx (via merger with Kadimastem) – A regenerative cell therapy targeting insulin-dependent diabetes
Why This Matters
NLS isn’t just riding the momentum of emerging markets in ADHD and sleep disorders — they’re seeking to build long-term value through intelligent pipeline development, strategic IP, and a focus on real-world, unmet clinical needs. And now, with its entrance into the fight against opioid addiction, NLSP adds a compelling new dimension to its mission.
In a market that punishes hype and rewards substance, NLSP is on the path to quietly execute.
NLS Pharmaceutics CEO Issues Letter to Shareholders
ZURICH, March 10, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholder.
Dear Shareholders,
We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.
Strategic Merger with Kadimastem
In November 2024, we announced a definitive merger agreement with Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), a clinical-stage cell therapy company specializing in “off-the-shelf” allogeneic cell products for neurodegenerative diseases and diabetes. This merger aims to create a Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies. Both companies’ boards of directors have unanimously approved the transaction, with Kadimastem’s shareholders recently voting in favor and NLS major shareholders holding approximately 40% of NLSs’ common shares having signed support letters for the NLS shareholders’ meeting to be convened soon. We currently anticipate closing the merger in the second quarter of 2025, pending effectiveness of NLSs’ pending registration statement filed with the Securities and Exchange Commission (“SEC”), Nasdaq approval, NLSs’ shareholders’ approval and customary closing conditions.
Regulatory Filings and Approvals
We filed a Registration Statement on Form F-4 and subsequent amendment with the SEC, detailing the proposed merger with Kadimastem. This filing is a necessary step toward finalizing the merger and creating a combined entity focused on innovative therapies. In addition, we have submitted an application to list the merged company on Nasdaq under the name of “NucelX Ltd.”, with the future ticker of NCEL.
Advancements in Diabetes Treatment
In collaboration with iTolerance Inc., Kadimastem has successfully completed a pre-Investigational New Drug (“pre-IND”) meeting with the U.S. Food and Drug Administration(“FDA”) for iTOL-102, a potential breakthrough therapy for Type 1 Diabetes. This innovative approach combines Kadimastem’s IsletRx cells with iTolerance’s immunomodulator, aiming to cure Type 1 Diabetes without the need for lifelong immune suppression.
The diabetes treatment landscape has experienced significant growth, underscored by notable mergers and acquisitions. For instance, Novo Nordisk’s acquisition of Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Similarly, Roche’s $2.7 billion acquisition of Carmot Therapeutics reflects their concerted effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe that these developments underscore the sector’s robust growth and the immense potential it holds for innovative treatments.
Furthermore, we are expanding our diabetes treatment strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes management, including neuroinflammation and metabolic resilience.
Advancements in Neurodegenerative Disease Treatment
Post-merger, we plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic Lateral Sclerosis (ALS). This trial is slated to commence following the merger’s completion, marking significant progress in our neurodegenerative disease treatment pipeline.
Experienced International Leadership Team
We believe that Kadimastem contributes to the merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine from the laboratory to the market. For example, Rebif®, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono. In addition, Ronen Twito, Kadimastem’s Executive Chairman and Chief Executive Officer, brings extensive experience working in the U.S. capital market and M&A international market.
Advancements in DOXA R&D Programs
Our promising Dual Orexin Receptor Agonist (“DOXA”) platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds’ potential to transform patient care.
Additional Pipeline Expansion and Research Initiatives
Our commitment to addressing critical health challenges remains steadfast:
- Fentanyl Dependence Treatment: We have launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating the opioid crisis.
- Advancing Scientific Research: Our recent submissions to and upcoming poster presentation at the American Society of Clinical Psychopharmacology’s 2025 Annual Meeting highlight our commitment to innovative therapeutic strategies and groundbreaking research.
Financial Resilience and Growth
We have fortified our financial foundation through strategic initiatives:
Nasdaq & Strong Financial Position
- We carry zero long-term debt, a rarity among biopharmaceutical companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints.
- We raised approximately $4.2 million pursuant to private placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private placements has extended our operational runway to approximately 18 months.
- This financial stability empowers us to accelerate clinical development, pursue strategic partnerships, and advance our innovative pipeline with confidence.
Looking Ahead
The momentum generated by these developments underscores our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology landscape, driving NLS Pharmaceutics toward a future of unparalleled success.
As we embark on this exciting new chapter, we remain laser-focused on:
- Building an international, strong, well-balanced pipeline and top-notch biotechnology company
- Delivering life-changing therapies for patients worldwide
- Expanding our pipeline through innovation & strategic collaborations
- Maximizing shareholder value by maintaining a strong financial position
We extend our deepest gratitude to our shareholders, partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.
Sincerely,
Alex ZwyerChief Executive Officer
NLS Pharmaceutics (NASDAQ: NLSP)
PIPELINE
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
- Centers for Disease Control and Prevention (the “CDC”) reported 105,007 drug overdose deaths – with 90% involving synthetic opioids like fentanyl
- Mazindol ER potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction.
- Mazindol ER is patent protected beyond September 2038
ZURICH, Jan. 28, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company dedicated to developing therapies for rare and complex central nervous system disorders, is proud to announce the launch of a preclinical program evaluating Mazindol ER (Extended-Release) as a novel treatment for fentanyl dependence. Fentanyl dependence is a major global health crisis and was recently declared a national public health emergency by the new Trump administration. In 2023, the CDC reported 105,007 drug overdose deaths with 90% involving synthetic opioids like fentanyl.
“The opioid epidemic, and specifically the rise of fentanyl dependence, presents an urgent medical need for innovative, non-opioid treatment approaches,” said Alex Zwyer, Chief Executive Officer of NLS. “We are committed to exploring the unique pharmacological profile of Mazindol, which targets multiple neurotransmitter systems implicated in opioid addiction. This preclinical program represents an important step in developing a potentially transformative therapy.”
Highlights of the Preclinical Program Mazindol, a tetracyclic compound with a distinct pharmacological profile, has shown potential in mitigating opioid dependence by acting on multiple neurotransmitter pathways, including:
- 5-HT1A receptor modulation: Regulates mood, anxiety, and reward pathways, addressing psychological aspects of opioid withdrawal.
- Mu-opioid receptor (“MOP”) interaction: Provides partial modulation of opioid effects, potentially reducing cravings and withdrawal symptoms without reinforcing addiction.
- Orexin-2 receptor (“OX2R”) partial agonist: Aids in restoring sleep-wake cycles and enhancing cognitive stability, which are significantly disrupted during opioid withdrawal.
Scientific RationaleFentanyl, a synthetic opioid that is up to 50 times more potent than heroin, has driven a global health crisis due to its high abuse potential and severe withdrawal symptoms. Traditional treatments, such as methadone and buprenorphine, often come with limitations, including risk of dependence and regulatory hurdles.
Mazindol ER offers a potential non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction while supporting recovery through its multimodal action on neurotransmitter systems. The sustained-release formulation provides a long-acting therapeutic effect, improving patient compliance and minimizing withdrawal-related disruptions.
Mechanism of Action of Mazindol ERMazindol’s unique pharmacodynamic properties position it as a promising candidate for opioid dependence treatment. Its mechanisms include:
- Inhibition of dopamine and norepinephrine transporters, restoring neurochemical balance and reducing cravings.
- 5-HT1A receptor modulation, potentially alleviating anxiety and depressive symptoms associated with withdrawal.
- MOP agonist activity, which may help mitigate opioid withdrawal symptoms while preventing full opioid reinforcement.
- Partial OX2R agonist activity, aiding in circadian rhythm regulation and reducing the impact of opioid-induced sleep disturbances.
Preclinical Study Objectives and Next Steps
The preclinical study, designated Study KO-943, will focus on:
- Evaluating the safety and efficacy of Mazindol ER in fentanyl dependence models.
- Assessing pharmacokinetics and pharmacodynamics in opioid-exposed subjects.
- Exploring the impact of Mazindol ER on craving reduction, withdrawal mitigation, and cognitive performance.
The study is expected to be completed within 12-18 months. Upon successful results, NLS will potentially seek regulatory pathways to advance to clinical development.
“We believe that Mazindol ER could offer a paradigm shift in opioid addiction treatment,” added Dr. Konofal, M.D./PhD, Chief Scientific Officer of NLSP. “Our stepwise development plan prioritizes early-stage investment to generate critical data that will pave the way for larger-scale studies and potential commercialization opportunities.”
Existing Patent Portfolio
NLS Pharmaceutics has secured several patents supporting the development of Mazindol ER:
- United States Patent No. 11,207,271: Covers oral formulations containing immediate-release and sustained-release layers of mazindol and their use in treating attention deficit disorders (“ADHD”) as well as sleep disorders.
- United States Patent No. 11,596,622: Granted for the use of Mazindol ER in the treatment of heroin dependence, providing a new therapeutic strategy for opioid use disorder.
These patents strengthen the Company’s intellectual property position and support the ongoing development of Mazindol ER for various indications.
Future Outlook
NLS aims to utilize initial findings to expanded research and potential commercialization of Mazindol ER in the treatment of fentanyl dependence. Other pipeline candidates include:
- NLS-4 (Lauflumide): A wake-promoting agent with applications in military and emergency response.
- NLS-11 (Benedin): A circadian rhythm modulator with potential applications for space missions and the ultra-rare Kleine-Levin Syndrome (KLS).
- NLS-3 (Levophacetoperane SR): A novel treatment for ADHD and Autism Spectrum Disorders, with potential pro-drug development.
Lead Asset: Mazindol ER
Mazindol ER is a patented and proprietary formulation of the active compound mazindol, and are designed for once-daily dosing. Mazindol has a well-established safety record from its long history of clinical use in the United States and in Europe when the drug was approved in an immediate release formulation for the management of obesity. Mazindol was marketed for nearly 30 years under the trade name Sanorex® before being voluntarily withdrawn from the market, and the drug is no longer available nor marketed in these regions. During its time on the market, mazindol was also widely used off-label and prescribed under compassionate use for the treatment of narcolepsy for several decades. Use in these compassionate use programs has yielded evidence of positive efficacy in patents suffering from the symptoms of narcolepsy including patients that were refractory to approved treatments for the disorder. Additionally, these same programs, a retrospective analysis of investigator sponsored studies, and NLS’s own trial evaluating Mazindol ER in patients with ADHD provide evidence of the drug’s favorable safety profile at doses that yielded efficacy signals.
We believe that our lead product candidate, Mazindol ER, offers a differentiated profile with clincally meaningful advantages over current treatment options for narcolepsy for the following reasons:
Mechanism of action
If approved, Mazindol ER would be the only partial orexin 2 receptor agonist as well as the only triple monoamine reuptake inhibitor approved by the FDA for the treatment of narcolepsy. Narcolepsy is caused by a profound loss of orexin producing neurons. A partial orexin 2 receptor agonist may help to replace missing endogenous orexin peptide, addressing the underlying cause of the disease. In addition, the drug’s action as a triple monoamine reuptake inhibitor can further reduce disease specific symptoms, offering patients a treatment option that may address the two primary symptoms of narcolepsy – excessive daytime sleepiness (EDS) and cataplexy attacks – in a convenient once-daily oral tablet.
Low potential for abuse, misuse, and diversion.
Mazindol is currently classified by the DEA as a Schedule IV controlled substance . The DEA defines Schedule IV controlled substances as those “with a low potential for abuse and a low risk of dependence”. Unlike Xyrem® (sodium oxybate), the top-selling treatment for narcolepsy in the United States deemed to have a high potential for abuse/misuse (Schedule III), mazindol was never required by the FDA to have a risk evaluation and mitigation strategy (REMS) program in place to manage known or potential serious risks associated with its use.
Quilience® has potential to be administered as a monotherapy.
Narcolepsy is a difficult disorder to manage and even with available treatments, the majority of narcolepsy patients often require multiple medications to treat their symptoms. According to the current treatment guidelines (initially published in 2007) of the American Academy of Sleep Medicine, or AASM, medications for narcolepsy, at best, provide only moderate improvement in narcolepsy symptoms, and their respective side effects may limit their use. The AASM specifically highlights that future investigations should be directed toward more effective and better tolerated therapies for treatment. The Voice of the Patient report from the FDA’s patient-focused drug development initiative, published in 2014, concluded that, based on the overall benefit-risk assessment of current medications, there is a continued need for additional effective and tolerable treatment options for patients with narcolepsy. A retrospective analysis (Nittur et.al, Sleep Med. 2013 Jan;14(1):30-6) showed that mazindol has a long-term, favorable benefit/risk ratio in 60% of drug-resistant patients with hypersomnia, including a clear benefit on the two primary symptoms of narcolepsy–EDS and cataplexy.
Mazindol ER is being developed as a once-daily oral tablet administered in the morning upon wakening.
Patients have identified a need for treatment options that are easier to take, dosed less frequently, do not disrupt nighttime sleeping, and provide full day coverage of symptoms. We believe that once-daily dosing with Mazindol ER may address this need and may help improve patient compliance and adherence with treatment. Mazindol ER utilizes our patented and proprietary extended-release (ER) formulation and is being designed to optimize its pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long-acting symptom control to uniquely meet the needs of patients.
Relationship Between Narcolepsy and ADHD
Narcolepsy and psychiatric disorders have a significant but under-recognized relationship in which the two may coexist. However, narcolepsy is frequently misdiagnosed initially as a psychiatric condition, contributing to protracted times for accurate diagnosis and treatment. Narcolepsy is a disabling neurological condition that carries a high risk for the development of social and occupational dysfunction. Deterioration in function associated with narcolepsy may lead to the secondary development of psychiatric symptoms and inversely, the development of psychiatric symptoms can lead to a deterioration in function and quality of life. The overlap in treatments may further enhance the difficulty to distinguish between diagnoses.
ADHD is the most common neurobehavioral disorder characterized by symptoms of inattention, impulsivity and hyperactivity with an estimated prevalence rate of approximately 4-12% worldwide, as reported by the paper, “Understanding Attention Deficit/Hyperactivity Disorder From Childhood to Adulthood,” by Drs. Timothy E. Wilens and Thomas J. Spencer.
On the surface, ADHD may appear to be the opposite of narcolepsy; however, there may actually be significant clinical similarities between the two disorders. Cumulative data on sleep problems in children and adolescents with ADHD have shown that children with ADHD have had a higher rate of restless sleep, impaired sleep, and daytime sleepiness than children without ADHD. However, it is unclear whether EDS in ADHD is due to nocturnal sleep disturbances or primary vigilance disorders because shorter sleep onset latency is assessed in ADHD patients by the Multiple Sleep Latency Test, rather than in the control group irrespective of the presence/absence of sleep disturbances.
Alternatively, problems with sleep may represent an intrinsic component of ADHD. The presence of ADHD symptoms in children and adolescents with narcolepsy has been found to be about two-fold higher than in the general control population. Adults with narcolepsy have been found to have a much greater likelihood of having a diagnosis of ADHD in childhood compared to the general control population. Hyperactivity seen in ADHD may, in fact, be a compensatory response for individuals who are under-aroused or sleepy, and ADHD symptoms contribute to poor quality of life and increased frequency of depressive symptoms, similar to narcolepsy. To the best of our knowledge, almost all of the treatments used in ADHD have mechanistic overlap with treatments used in narcolepsy for EDS, and researchers suggest that the symptoms of EDS, fatigue, and sleep fragmentation may be the cause for ADHD symptoms, which is consistent with similar findings in other hypersomnia disorders.
AstroRx, the medical product for ALS treatment that is being researched by Kadimastem, the company NLSP has signed a binding merger agreement with, was granted Orphan drug status by the FDA. This status grants the company that manufactures the drug marketing exclusivity for 7 years from the date of receipt of marketing approval of the drug. The recognition of orphan drug status also enables accelerated examination and response paths from the FDA and other regulatory authorities.
Additionally, Kadimastem is focused on the generation and manufacturing of pancreatic insulin secreting islets (IsletRx) from embryonic stem cells for the treatment of insulin dependent diabetes such as Type 1 Diabetes. This program is in pre-clinical phase and they are moving fast down the regulatory path to start human trials. The number of patients with diabetes was estimated to be over 366 million worldwide in 2011 and is projected to be more than 552 million in 2030. The American Diabetes Association (ADA) estimated the total annual costs of diabetes to be US$223.5 billion (in the US alone). The global cost is estimated to be US$465 billion annually and will grow to about US$510 billion by 2030.
MANAGEMENT TEAM
AlexZwyer, MBA
Chief Executive Officer & Co-Founder
A co-founder of the company with extensive operational, C-level pharmaceutical experience as well as a serial entrepreneur and strong leader with a proven track-record.
Alex Zwyer has served as our Chief Executive Officer and as a Director since our incorporation in August 2015. Mr. Zwyer has over 25 years of international business experience of which more than 10 years as a C-level executive in the pharma/biotech field. In 2007, prior to, and until founding NLS in 2015, Mr. Zwyer founded a startup in the high-end luxury food sector, and served as its chief executive officer until 2015 when he successfully sold the company. From 1991 and until 2007, Mr. Zwyer served in various positions with Viforpharma AG (SWX: VIFN) (then known as Vifor (International) Inc.), most notably serving as Executive Vice President (chief operating officer), leading the company’s global regulatory affairs, medical affairs, sales and marketing as well as business development teams. Mr. Zwyer speaks seven languages fluently. Mr. Zwyer holds a B.B.A. in business administration from Oekral, Zurich, Switzerland and an executive M.B.A. from GSBA/Lorange Institute of Business, Zurich, Switzerland and an M.B.A. from University at Albany SUNY.
GeorgeApostol, MD MS
CMO & Global Head R&D
Dr. Apostol’s career spans more than 20 years in pharma industry and consists of a broad drug development expertise across early, middle and late phases of development at the global R&D organizations of Eli Lilly, Pfizer, Abbott, Novartis, Shire and Endo.
His main areas of capability include orphan diseases in CNS, in particular Fragile X Syndrome, Alagille Syndrome, but also ADHD, anxiety, depression, migraine, Parkinson’s and schizophrenia. He has built multiple drug development teams both in the US and Europe, several receiving distinguished corporate R&D awards and achieving multiple regulatory approvals in US, EU and Japan. He holds a MD degree from the Carol Davila Medical School in Romania and a MS in Clinical Research from University of Minnesota.
EricKonofal, MD, PhD
Chief Scientific Officer and Co-Founder
A co-founder of the company with a deep knowledge and experience in clinical and scientific research. He is also a drug-hunter & pipeline developer for sleep disorders as ADHD.
Dr. Konofal is a primary clinical and international scientific researcher, and is an accomplished drug hunter and drug pipeline developer. He is a senior medical consultant for the Pediatric Sleep Disorders Center at Robert-Debre University of Paris (APHP). Dr. Konofal served as Principal Clinical Investigator at the Clinical Pharmacology & Pharmacogenetic Department at Robert-Debre University of Paris. His research has focused on brain- and iron-dopamine interactions in subjects with neurological sleep disorders (RLS, PLMS), and ADHD. Additionally, Dr. Konofal served as a consultant at the sleep disorder center of Pitié-Salpêtrière University Hospital Group (APHP), specializing in ADHD, RLS, PLMS and CDH. He initiated previous studies based on iron and its role in the pathophysiology of ADHD, and has conducted extensive research on the relationship between the brain and iron.
He launched a clinical trial on the efficacy of mazindol in children with ADHD (clinicaltrials.gov identifier: NCT00508677) and obtained the U.S. patent for mazindol in the treatment of ADHD. Dr. Konofal wrote the scientific rationale for Nolazol® and discovered the pharmacological profile of mazindol and its orexin-2 receptor binding properties. He has authored over 70 peer-reviewed publications in the area of sleep disorders and other CNS diseases.
NEWS
Mar 31, 2025
NLS Pharmaceutics CEO Issues Letter to Shareholders
Mar 10, 2025
Feb 27, 2025
Feb 25, 2025
Feb 25, 2025
Feb 10, 2025
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
Jan 31, 2025
Jan 30, 2025
Jan 28, 2025
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
Jan 16, 2025
Jan 8, 2025
Dec 30, 2024
Dec 19, 2024
NLS Pharmaceutics CEO Issues Letter to Shareholders
Dec 11, 2024
Dec 4, 2024
Dec 3, 2024
Nov 18, 2024
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
Nov 4, 2024
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
Oct 28, 2024
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
Oct 21, 2024
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF FIVE THOUSAND TWO HUNDRED FIFTY USD BY LFG EQUITIES CORP FOR A ONE DAY NLSP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.